Lamprene 50mg. 100mg Gelatine Capsules
PDF Leaflet Revision Date: 22 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multibacillary leprosy and multidrug-resistant tuberculosis (MDR-TB).
Dosage (summary)
Leprosy: Adults 300 mg on Day 1, then 50 mg daily; MDR-TB: Adults u226530 kg: 100 mg/day; <30 kg: 50 mg/day.
Onset of Action / Duration
Onset: 50 days, Duration: Not specified.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; crosses placenta and may harm fetus; avoid breastfeeding.
Key Drug Interactions
- CYP3A substrates
- QT prolonging medicines
Contraindications
- Hypersensitivity to clofazimine
- QT interval prolongation
- Concomitant use with QT prolonging medicines
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Skin discolouration
- QT prolongation
Counselling Points
- Take with food or milk
- Adhere to treatment regimen
- Report any signs of adverse reactions
Serious warnings
- QT prolongation
- Risk of Torsades de Pointes
- Gastrointestinal disturbances
Important Disclaimer
The Lamprene 50mg. 100mg Gelatine Capsules professional information leaflet below is the property of Novartis and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
